

Screening for ASD Systematic Evidence Review Full Text Review Form

First Author, Year: _____ Reference ID #: _____ Initials: ____ ____ ____

1. Does the study address screening measures for ASD?	Yes	No
2. Is the study original research (includes systematic review or meta-analysis)?	Yes	No
3. Does the study include individuals in the target population (children screened for ASD between 12-36 months of age)? a. Record age range (mean+SD and/or range) _____	Yes	No
4. Does the study provide data related to at least one of the following? <ul style="list-style-type: none"> • Performance characteristics of tests to screen for ASD in children between 12-36 months of age (provides sensitivity, specificity, PPV, NPV or data to calculate) • Harms or long-term clinical outcomes of screening for children between 12-36 months of age/families of such children (e.g., behavioral changes, distress, misclassification, other unintended consequences) 	Yes	No
5. Record setting in which screening occurs (e.g. primary care, early intervention preschool)		
6. Was the study conducted in one of the following countries: Andorra, Argentina, Australia, Austria, Bahrain, Barbados, Belgium, Brunei Darussalam, Canada, Chile, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong (China), Hungary, Iceland, Ireland, Israel, Italy, Japan, Republic of Korea, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, New Zealand, Norway, Poland, Portugal, Qatar, Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States	Yes	No
7. Does the study include an exposure/screening group and comparison group? (Note: This question for data collection only-- does not affect inclusion)	Yes	No
8. If excluded, retain this paper for contextual questions or review of references (performance characteristics of diagnostic tools, stability of diagnosis, resources available for screening, treatment resources available)?	Yes	No